Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

Thrombosis Research

Volumn 124, Issue 1, 2009, Pages 96-100

  Hedegaard, Sofie S ^a   Hvas, Anne Mette ^a   Grove, Erik L ^a   Refsgaard, Jens ^a   Rocca, Bianca ^b   Daví, Giovanni ^b   Kristensen, Steen D ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

11 dehydro thromboxane B2; Aspirin; Drug resistance; Patient compliance; Platelet aggregation; Thromboxane B2

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CREATININE; CYCLOOXYGENASE 1; THROMBOXANE; THROMBOXANE B2;

ADULT; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HUMAN; INTERVIEW; LABORATORY TEST; LOW DRUG DOSE; MALE; METABOLITE; OPTICAL PLATELET AGGREGOMETRY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; THROMBOCYTE AGGREGATION;

ADULT; AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TABLETS, ENTERIC-COATED; THROMBOXANES; TIME FACTORS;

EID: 64649098177     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.12.034     Document Type: Article

References (34)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Davi G., and Patrono C. Platelet activation and atherothrombosis. N Engl J Med 357 (2007) 2482-2494
3. Maree A.O., and Fitzgerald D.J. Aspirin and coronary artery disease. Thromb Haemost 92 (2004) 1175-1181
4. Chakroun T., Addad F., Abderazek F., Ben-Farhat M., Hamdi S., Gamra H., et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 121 (2007) 413-418
5. Mortensen J., Poulsen T.S., Grove E.L., Refsgaard J., Nielsen H.L., Pedersen S.B., et al. Monitoring aspirin therapy with the Platelet Function Analyzer-100. Scand J Clin Lab Invest (2008) 1-7
6. Madsen E.H., Schmidt E.B., Maurer-Spurej E., and Kristensen S.R. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 19 (2008) 335-341
7. Nielsen H.L., Kristensen S.D., Thygesen S.S., Mortensen J., Pedersen S.B., Grove E.L., et al. Aspirin response evaluated by the VerifyNowtrade mark Aspirin System and Light Transmission Aggregometry. Thromb Res 123 (2008) 267-273
8. Tran H.A., Anand S.S., Hankey G.J., and Eikelboom J.W. Aspirin resistance. Thromb Res 120 (2007) 337-346
9. Gasparyan A.Y., Watson T., and Lip G.Y. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51 (2008) 1829-1843
10. Patrono C., and Rocca B. Drug insight: aspirin resistance-fact or fashion?. Nat Clin Pract Cardiovasc Med 4 (2007) 42-50
11. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
12. Dorsch M.P., Lee J.S., Lynch D.R., Dunn S.P., Rodgers J.E., Schwartz T., et al. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother 41 (2007) 737-741
13. Marcucci R., Paniccia R., Antonucci E., Poli S., Gori A.M., Valente S., et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 98 (2007) 844-851
14. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167 (2007) 1593-1599
15. Krasopoulos G., Brister S.J., Beattie W.S., and Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336 (2008) 195-198
16. Shantsila E., and Lip G.Y. 'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?. J Transl Med 6 (2008) 47
17. Patrono C., and Rocca B. Drug insight: aspirin resistance-fact or fashion?. Nat Clin Pract Cardiovasc Med 4 (2007) 42-50
18. Harrison P. Platelet function analysis. Blood Rev 19 (2005) 111-123
19. Patrignani P., Filabozzi P., and Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69 (1982) 1366-1372
20. Ciabattoni G., Maclouf J., Catella F., FitzGerald G.A., and Patrono C. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta 918 (1987) 293-297
21. Patrono C., Ciabattoni G., Remuzzi G., Gotti E., Bombardieri S., Di M.O., et al. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J Clin Invest 76 (1985) 1011-1018
22. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
23. Faraday N., Becker D.M., Yanek L.R., Herrera-Galeano J.E., Segal J.B., Moy T.F., et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 98 (2006) 774-779
24. Maree A.O., Curtin R.J., Dooley M., Conroy R.M., Crean P., Cox D., et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 46 (2005) 1258-1263
25. McCabe D.J., Harrison P., Mackie I.J., Sidhu P.S., Lawrie A.S., Purdy G., et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 16 (2005) 269-280
26. Perneby C., Wallen N.H., Rooney C., Fitzgerald D., and Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95 (2006) 652-658
27. Schwartz K.A., Schwartz D.E., Ghosheh K., Reeves M.J., Barber K., and DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95 (2005) 973-975
28. Frelinger III A.L., Furman M.I., Linden M.D., Li Y., Fox M.L., Barnard M.R., et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113 (2006) 2888-2896
29. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
30. Cox D., Maree A.O., Dooley M., Conroy R., Byrne M.F., and Fitzgerald D.J. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37 (2006) 2153-2158
31. Patrono C., Ciabattoni G., Pugliese F., Pierucci A., Blair I.A., and FitzGerald G.A. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 77 (1986) 590-594
32. Catella F., and FitzGerald G.A. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 47 (1987) 647-656
33. Muir A.R., Patterson C., McMullin M.F., and McKeown P.P. Assessment of Aspirin Resistance Varies on a Temporal Basis in Patients with Ischaemic Heart Disease. Heart (2008)
34. Karon B.S., Wockenfus A., Scott R., Hartman S.J., McConnell J.P., Santrach P.J., et al. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. Clin Chem 54 (2008) 1060-1065